View Single Post
Old 04-16-2008, 06:25 AM   #5
Hopeful
Senior Member
 
Join Date: Aug 2006
Posts: 3,380
Here is another article on the same subject

from Medscape. You may have to register to view:

http://www.medscape.com/viewarticle/572995

The key finding:

"What was most surprising in this study was that patients with low-HER2/neu-expressing tumors responded so well to the vaccine. In fact, Dr. Benavides pointed out, the patients with low-expressing (0 to 2+ on immunohistochemistry [IHC]) HER2/neu tumors had a better response to the vaccine than women with higher-expressing tumors. They experienced not only a better immune response, but a better clinical one as well, as demonstrated by a decreased rate of breast cancer recurrence and 0% mortality after E75 peptide vaccination."

Hopeful
Hopeful is offline   Reply With Quote